Lifetime Crystals Launches The Retro Revival Collection

In a world where memories are fleeting and digital photos vanish into the cloud, Lifetime Crystals is bringing them back to earth—literally. The custom gift shop today announced the launch of its Retro Revival Collection, a nostalgic nod to the past with a futuristic twist: laser-etched 3D photo crystals that transform cherished moments into timeless, tactile art.

Crafted from optically clear crystal and etched with precision lasers, each piece captures a personal photo in stunning three-dimensional detail. Whether it’s a sepia-toned wedding portrait, a Polaroid-style pet snapshot, or a groovy family vacation pic, the Retro Revival Collection turns vintage vibes into modern heirlooms.

“People are craving authenticity and emotional connection,” said a spokesperson for Lifetime Crystals. “This collection is about honoring the past while celebrating the present—with a gift that literally shines.”

The collection features a variety of shapes and sizes, including heart, tower, and diamond designs, all customizable with text and available with LED light bases for a radiant display. Each crystal is made in the USA and ships in 1–2 days, making it a perfect last-minute gift that doesn’t feel last-minute.

From anniversaries to graduations, memorials to just-because moments, Lifetime Crystals’ Retro Revival Collection is the ultimate way to say, “Remember this?”

Availability: The Retro Revival Collection is available now at LifetimeCrystals.com.

About Lifetime Crystals:

Lifetime Crystals specializes in personalized 3D laser-etched photo gifts that preserve life’s most meaningful moments. With a commitment to craftsmanship, clarity, and customer care, the company has become a go-to destination for unforgettable keepsakes.

Media Contact
Company Name: Lifetime Crystals
Contact Person: Paz
Email: Send Email
City: LOS ANGELES
State: CALIFORNIA
Country: United States
Website: lifetimecrystals.com

Wooldridge Law Injury Lawyers Launches Dedicated Truck Accident Division and New Bilingual Campaign in Las Vegas

Wooldridge Law Injury Lawyers Launches Dedicated Truck Accident Division and New Bilingual Campaign in Las Vegas

Truck accident lawyer

LAS VEGAS, Nev. – Wooldridge Law Injury Lawyers, a premier personal injury firm based in Las Vegas, has launched a new Dedicated Truck Accident Division aimed at providing specialized legal support to victims of commercial vehicle collisions. The initiative is part of a broader campaign to expand access to justice for injured drivers, families of victims, and commercial truck operators throughout Southern Nevada.

The firm’s new division is staffed with experienced attorneys focused solely on complex truck accident cases involving catastrophic injuries. With services including 24/7 case response and bilingual legal assistance, Wooldridge Law Injury Lawyers is reinforcing its commitment to delivering responsive, results-driven representation to the communities it serves.

“Truck accidents are among the most devastating incidents we handle, and they require focused legal strategy and immediate intervention,” said Nicholas Wooldridge, founder and managing attorney. “By establishing this dedicated division and launching a bilingual outreach effort, we’re ensuring our clients get the attention, access, and aggressive advocacy they deserve — day or night.”

The campaign includes Spanish-language services, community outreach, and targeted messaging to raise awareness about legal rights and resources following a truck accident. Wooldridge Law Injury Lawyers has long advocated for accessibility in legal services, and the expansion ensures that both English and Spanish-speaking residents receive comprehensive representation.

Wooldridge Law Injury Lawyers’ new division is equipped to handle a wide range of truck accident cases, including those involving severe injuries, wrongful death, and complex liability issues. The firm’s attorneys bring deep knowledge of federal and state trucking regulations and leverage this expertise to secure maximum compensation for clients.

“Our mission has always been to serve the injured with integrity, urgency, and excellence,” Wooldridge added. “This expansion reflects our ongoing promise to overdeliver in every case and fight for justice at every turn.”

Those injured in a truck accident are encouraged to contact Wooldridge Law Injury Lawyers for a free consultation. The firm offers immediate legal assistance 24 hours a day, seven days a week.

About Wooldridge Law Injury Lawyers

Wooldridge Law Injury Lawyers is a Las Vegas-based firm focused exclusively on personal injury law. Known for its trial experience, aggressive representation, and client-first approach, the firm has helped thousands of Nevadans secure justice and compensation. With bilingual support and 24/7 availability, Wooldridge Law Injury Lawyers is committed to fighting for the rights of accident victims statewide.

Media Contact
Company Name: Wooldridge Law Injury Lawyers
Contact Person: Adam Plumer
Email: Send Email
Phone: (702) 867-8900
Address:400 S 7th St, Ste 490
City: Las Vegas
State: Nevada
Country: United States
Website: https://getthewin.com/

Introducing Kreebo: The AI Storytelling App Helping Kids Unlock Their Inner Genius – Safely and Creatively

In a world where technology is everywhere and screen time is often met with guilt, one app is flipping the narrative for families. Meet Kreebo, the AI-powered storytelling companion built especially for children—a magical space where imagination blossoms, creativity flows freely, and screen time becomes something to celebrate.

Kreebo officially launches today, promising something rare and powerful: a safe, child friendly AI experience that helps kids bring their wildest ideas to life—one story at a time.

Because every child has a story to tell.

Parent’s Problem Turned Into a Global Solution

Kreebos story began with one fathers heartbreak.

“My 8-year-old son had incredible ideas—whole worlds he’d imagine during bedtime or car rides,” said the founder of Kreebo. “But when it came time to draw or write them, he’d struggle. His thoughts were vivid, but his words couldn’t keep up. He got frustrated. I searched everywhere for a tool that could help him turn those ideas into something real—and I couldn’t find one.”

So, he built it.

Kreebo was born to bridge that gap: a magical AI friend who listens to kids, chats with them, and helps turn their ideas into beautifully illustrated storybooks. No pressure. No perfection required. Just imagination—and a safe space to grow it.

What Makes Kreebo Dierent?

Kreebo isn’t like the tech tools parents are used to. There are no games filled with ads, no endless scrolling, and no algorithms mining data.

What children get instead is:

• A guided storytelling experience through friendly AI chat

• A way to co-create storybooks they can be proud of

• A tool that’s age-appropriate, ad-free, and safe

• Illustrated books they can read, share, and revisit

• A feeling of confidence and joy that comes from being heard

Unlike generic apps, Kreebo was designed hand-in-hand with parents, teachers, illustrators, and child development experts. It respects children’s emotional world—and protects it.

“Kreebo is the one time I don’t feel guilty about screen time,” said one mother of two. “My daughter’s not just watching cartoons. She’s creating worlds. And she’s so proud of what she makes.”

The Science Behind the Magic

According to Dr. John Medina, a developmental molecular biologist and author of Brain Rules for Baby, early childhood is marked by an extraordinary burst in neural connections.

“Children’s brains are wired for learning and creativity,” he explains. “During early development, they form more neural connections than at any other time in life. This is what gives young kids that boundless potential.”

However, without stimulation, those connections are pruned away. The brain becomes more specialized, but it also loses some of its raw creative power.

That’s why Kreebo matters.

By giving kids the space, encouragement, and tools to create freely, Kreebo helps them explore their ‘genius’ phase—turning fleeting ideas into something lasting and meaningful.

“We can’t stop time,” says the founder. “But we can make sure that while they’re young, children have a platform to express their true, unfiltered imagination. And that’s what Kreebo gives them.”

Kids Dont Just Play with Kreebo. They Create.

Children as young as six are now publishing books through Kreebo.

They write about alien cupcakes, lost puppies in New York City, magical forests guarded by talking owls, and superheroes who wear glittery sneakers. Kreebo listens patiently, offers prompts when they’re stuck, and celebrates every twist and turn of their story.

And then? It brings those tales to life—with vibrant illustrations and a beautifully formatted digital book they can read, print, or share.

Some of Kreebo’s young authors have already created multiple books. For many, it’s their first time seeing themselves as storytellers.

“I made a book! Like a real book!” exclaimed an excited 7-year-old user.

“I showed it to my grandma and she cried.”

Built with Care. Backed by Purpose.

Kreebo’s team is made up of designers, educators, and parents who understand the delicate balance of screen time and meaningful engagement. They know how hard it is to find tech that doesn’t just occupy a child’s time—but enriches it.

“Our mission is simple: to give kids something good on their screens,” says co-founder Saraf Talukder. “Something that feeds their imagination instead of draining it.”

And because safety is non-negotiable:

• Kreebo never exposes kids to open web content

• There are no in-app purchases, pop-ups, or hidden costs

• Conversations are guided, moderated, and age-aligned

• Stories are created in a closed, protected environment

A Platorm for Every Child

Whether a child is 6, 8, or 10, Kreebo meets them where they are. Whether they love writing or dread it. Whether they’re brimming with ideas or just need a nudge. Every child gets to be an author.

For parents, it’s a way to turn downtime into something they can be proud of.

“I’ve tried so many apps for my kids,” shared one father. “Most of them are either too complicated or too mindless. But Kreebo hits that perfect balance. My son is talking to an AI— but it feels like talking to a friend who helps him dream bigger.”

The Future of Storytelling Starts Here

Kreebo is more than just an app. It’s a movement toward joyful, safe, purposeful tech for children.

It proves that AI, when used mindfully, can nurture the most human thing of all: imagination.

What started as a solution for one child is now a platform built for every child. Because every child has a story to tell, Kreebo just helps them tell it.

ABOUT KREEBO

Kreebo is a child-friendly AI storytelling platform co-founded by Saraf Talukder and Wahid Choudhury, designed to help children turn their imagination into beautifully illustrated books. Built with safety, creativity, and education in mind, Kreebo transforms screen time into story time—without ads, distractions, or pressure. Through a playful, guided chat experience, kids become proud authors while parents finally have a screen activity they can feel good about.

Learn more at: www.kreebo.com

Download the App:

iOS: https://apps.apple.com/us/app/kreebo/id6743721247

Android: https://play.google.com/store/apps/details?id=com.gurho.kreebo

Media Contact
Company Name: Kreebo
Contact Person: Saraf Talukder
Email: Send Email
Country: United States
Website: www.kreebo.com

NYFA Spotlights Alumna Mimi Masters Scholarship Opens Doors for Emerging Filmmakers

LOS ANGELES – Jun 18, 2025 – The New York Film Academy (NYFA) today celebrated alumna Mimi Masters for her dual impact on the screen-content landscape and on access to graduate-level film education. Masters — Chief Executive Officer of IMC Film Production — recently introduced FILM SNAP, a vertical-drama app now live on iOS and Android, and has endowed an annual NYFA Scholarship that fully funds the MFA studies of students from historically marginalized communities.

FILM SNAP allows creators to upload 9:16 shorts, reach a global audience, and receive professional curation. “The app is a bridge between mobile viewers and the next wave of directors,” Masters said. By underwriting tuition for promising filmmakers who lack financial resources, her scholarship extends that same bridge from the classroom to the set — ensuring that talent discovered through education can immediately find a home on FILM SNAP’s global stage. Andrzej Barkowiak, Academy Award-winning filmmaker and FILM SNAP’s Chief Recommending Officer, praised the concept: “Fresh perspectives drive cinema forward. FILM SNAP gives new filmmakers a runway from their phones to the world screen — exactly what the industry needs.”

David Picci, the first scholarship recipient graduated from NYFA’s Los Angeles campus this spring and is currently developing a debut short. “This award turned an unlikely aspiration into a career,” the filmmaker said. “It proves that our stories can travel far beyond our neighborhoods.”

Dr. Joy Zhu, NYFA’s Executive Vice President and senior academic leader in Los Angeles, praised the initiative. “Mimi’s model combines innovation with inclusion,” Zhu noted. “By lowering the financial barrier and opening a distribution pathway, she helps ensure that the next generation of voices is as diverse as the audiences they hope to reach.”

Reflecting on her NYFA roots, Masters added, “The Academy taught me to point the camera toward the world I want to see. Giving back through scholarships — and providing a platform like FILM SNAP — lets me hand that lens to the next generation.”

About FILM SNAP

FILM SNAP is a mobile platform for vertical short-form drama, offering creators global reach, algorithmic discovery, and professional mentorship. The app is available worldwide on the App Store and Google Play.

About the New York Film Academy

Founded in 1992, NYFA delivers intensive, hands-on film, media, and performing-arts programs on campuses in Los Angeles, New York, Miami, Florence, and online. Its alumni network spans narrative, documentary, television, and emerging digital formats.

Media Contact
Company Name: Film SNAP LLC
Email: Send Email
Address:2600 W Olive Ave Burbank Suite 546
City: LA
State: CA 91505
Country: United States
Website: https://film-snap.ca/

Multiple Myeloma Clinical Trials Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Multiple Myeloma Pipeline Insights 2025” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Multiple Myeloma Treatment Landscape. Click here to read more @ Multiple Myeloma Pipeline Outlook

Key Takeaways from the Multiple Myeloma Pipeline Report

  • In June 2025, Celgene announced a study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who receive bridging therapy with talquetamab (Cohort 1b), in participants with multiple myeloma (MM) having progressed within 18 months of initial treatment with autologous stem cell transplantation (ASCT) (Cohort 2a) and without ASCT (Cohort 2b) or, in participants with inadequate response post ASCT during initial treatment (Cohort 2c) and the efficacy and safety of bb2121 used in combination with lenalidomide maintenance in participants with suboptimal response post ASCT (Cohort 3).
  • In June 2025, Bristol-Myers Squibb announced a study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
  • In June 2025, Novartis Pharmaceuticals announced a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma.
  • In June 2025, GlaxoSmithKline announced a study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).
  • In June 2025, AstraZeneca announced a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
  • In June 2025, Pfizer announced a study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
  • DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 75+ Multiple Myeloma companies working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
  • The leading Multiple Myeloma Companies such as CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
  • Promising Multiple Myeloma Pipeline Therapies such as TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

Discover groundbreaking developments in Multiple Myeloma therapies! Gain in-depth knowledge of key Multiple Myeloma clinical trials, emerging drugs, and market opportunities @ Multiple Myeloma Clinical Trials Assessment

Multiple myeloma Emerging Drugs Profile

  • Zevorcabtagene Autoleucel: Carsgen Therapeutics

Zevorcabtagene Autoleucel (Zevor-cel, R&D code: CT053) is an autologous fully human CAR T-cell product candidate against B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM). In October 2022, China National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) and has granted the priority review for zevor-cel. Zevor-cel is expected to be approved by the NMPA for the treatment of R/R MM at the end of 2023 or the beginning of 2024. In January 2023, CARsgen and Huadong Medicine entered into a collaboration agreement for the commercialization of CARsgen’s lead drug candidate, zevor-cel, in mainland China. Since reaching the agreement, teams from CARsgen and Huadong Medicine have been working together closely to implement this collaboration and prepare for the approval and commercialization of zevor-cel in China.

  • Descartes 08: Cartesian Therapeutics

Descartes-08 is an autologous BCMA-targeting RNA-modified CAR T-cell therapy. Descartes-08 is engineered by mRNA transfection to express anti-BCMA CAR for a defined length of time. Descartes-08 express anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs. The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity. In early-stage clinical studies, Descartes-08 has been safe and well-tolerated in patients with MG and multiple myeloma. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple Myeloma.

  • GC012F: Gracell Biotechnology Shanghai Co., Ltd.

GC012F is Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. GC012F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. Gracell has initiated a Phase 1b/2 trial evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in the United States and a Phase 1/2 clinical trial in China is to be commenced imminently.

  • CID-103: CASI Pharmaceuticals

CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that recognizes a unique epitope on CD38. It was engineered to have strong activity against CD38 malignant cells and to reduce certain safety issues observed with existing treatments. Preclinical data of CID-103 demonstrates enhanced activity against a broad array of malignancies which express CD38 and demonstrates a better preclinical safety profile when compared to other CD38 mAbs. These attributes offer the potential for accelerated development and regulatory review, including rapid advancement into earlier lines of therapy. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.

  • STI-1492: Sorrento Therapeutics

STI-1492 is a therapeutic candidate developed by Sorrento Therapeutics for the treatment of relapsed or refractory multiple myeloma. It is an allogeneic, off-the-shelf therapy that involves the administration of Anti-CD38 A2 Dimeric Antigen Receptor T (DAR-T) cells through a single intravenous infusion. The therapy is currently being evaluated in a phase 1b, open-label, dose-escalation study involving subjects with relapsed or refractory multiple myeloma. CD38 is a transmembrane glycoprotein present on various immune cells and hematologic malignancies, and its expression has been associated with poor prognosis. Currently, the drug is in the Phase I stage of its development for the treatment of Multiple Myeloma.

The Multiple Myeloma Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Myeloma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma Treatment.
  • Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Myeloma market

Stay informed about the Multiple Myeloma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Multiple Myeloma Unmet Needs

Multiple Myeloma Companies

CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix and others.

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Multiple Myeloma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Multiple Myeloma Pipeline! See the latest progress in drug development and clinical research @ Multiple Myeloma Market Drivers and Barriers, and Future Perspectives

Scope of the Multiple Myeloma Pipeline Report

  • Coverage- Global
  • Multiple Myeloma Companies- CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
  • Multiple Myeloma Pipeline Therapies- TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.
  • Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Multiple Myeloma Pipeline Analysis Today! @ Multiple Myeloma Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Multiple myeloma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Multiple myeloma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Venetoclax: AbbVie
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. PHE885: Novartis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ONC 201: Oncoceutics
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. TNB 383B: TeneoBio
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Multiple myeloma Key Companies
  21. Multiple myeloma Key Products
  22. Multiple myeloma- Unmet Needs
  23. Multiple myeloma- Market Drivers and Barriers
  24. Multiple myeloma- Future Perspectives and Conclusion
  25. Multiple myeloma Analyst Views
  26. Multiple myeloma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Clinical Trials Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Clearview Window Coverings Leads the Way in Custom Window Home Elegance in the Pacific Northwest

Clearview Window Coverings, a leading provider of high-quality custom window treatments in the Pacific Northwest, is proud to announce an expanded range of services and an enhanced design experience for homeowners and commercial clients across Whatcom, Skagit, and Island counties. Known for its commitment to craftsmanship, personalized service, and design-forward solutions, Clearview Window Coverings continues to set the standard in custom window covering excellence.

Since its founding, Clearview Window Coverings has built a reputation for pairing style and function with unbeatable customer care. Whether it’s Bellingham roller shades, motorized shades for modern smart homes, energy-efficient blinds, or elegant draperies tailored to exact specifications, the Clearview team brings unmatched expertise to every project. From in-home consultations to professional installation, clients enjoy a seamless experience with results that speak for themselves.

“Our goal is simple,” says the Clearview team. “We want to help customers transform their space—not just with beautiful window treatments, but with solutions that enhance privacy, comfort, and energy efficiency. We’re here to listen, guide, and deliver custom results that truly fit their lifestyle.”

Clearview Window Coverings offers an impressive product line that includes:

  • Custom blinds, shades, and shutters

  • Motorized and smart-home integrated solutions

  • Designer drapery and valances

  • Energy-efficient and child-safe options

  • Sustainable materials and eco-friendly choices

Clients also benefit from Clearview’s consultative approach. Every design starts with an in-person or virtual consultation to assess lighting, aesthetics, functionality, and budget. Using top-tier brands and the latest design trends, Clearview Window Coverings offers creative solutions tailored to both new builds and remodels.

Clearview’s commitment to local service means they’re not just window covering experts—they’re community partners. From cozy waterfront homes in Bellingham to contemporary condos in Mount Vernon, Clearview has helped hundreds of clients achieve stylish, functional spaces.

In a world of online window treatment kits and DIY quick fixes, Clearview Window Coverings stands out by delivering a truly customized, high-touch experience that prioritizes quality, longevity, and local expertise.

Whether you’re upgrading your home’s style, improving energy efficiency, or completing a full renovation, Clearview Window Coverings is ready to guide you from inspiration to installation.

To learn more or schedule a free consultation, visit www.clearviewcoverings.com

About Clearview Window Coverings

Clearview Window Coverings is a trusted provider of high-quality window treatments based in Bellingham, WA. Offering a full range of blinds, shades, and drapery for indoor and outdoor applications, the company is dedicated to providing exceptional service and innovative, custom solutions.

From free in-home consultations to complimentary on-site measurements, Clearview Window Coverings helps clients create stunning, functional window designs tailored to their unique vision and budget.

Media Contact
Company Name: Clearview Window Coverings
Contact Person: Lariza Vinish
Email: Send Email
Country: United States
Website: https://www.clearviewcoverings.com

Julie Krause Revolutionizes Real Estate in Anacortes and Beyond

Anacortes, WA – With a commitment to personalized service and a deep understanding of the unique needs of homeowners and buyers, Julie Krause, a seasoned real estate professional with Coldwell Banker 360 Team, continues to elevate the real estate experience in Anacortes, Mt. Vernon, Sedro Woolley, and surrounding areas. Her passion for pairing people with their dream homes is reflected in her comprehensive suite of tools and services, all accessible through her streamlined website, juliekrause.cb360team.com.

Julie’s website offers a wide variety of properties, perfect for every lifestyle and budget. From charming rural homes in Sedro Woolley to modern properties in bustling Mt. Vernon, the listings are designed to meet the needs of buyers, whether they’re new to the market or looking for their forever home. With advanced search features, including mapping options and community-specific searches, finding the perfect home has never been more accessible.

For sellers, Julie offers a seamless solution with her home valuation tool. By inputting basic information about a home, sellers can receive an instant assessment of their property’s worth in today’s dynamic market. This feature not only simplifies the selling process but gives homeowners the confidence they need to make informed decisions.

Julie Krause’s personalized approach sets her apart in the competitive Mount Vernon real estate arena. “Buying or selling a home is one of life’s biggest decisions, and it deserves dedicated attention,” Julie explains. “I work closely with my clients to ensure they feel supported every step of the way, providing expertise, transparency, and solutions tailored just for them.”

One standout aspect of Julie’s service is her focus on community. Her website highlights featured communities in the area, including Anacortes, Skagit, Snohomish, and Whatcom Counties, allowing buyers to explore neighborhoods that suit their lifestyle. Additionally, Julie’s portal feature provides buyers and sellers with real-time notifications about open houses, price adjustments, and new listings, helping them stay ahead in the competitive market.

Julie also simplifies the home buying process with her property watch function, providing potential buyers with email updates when homes that match their criteria hit the market. By leveraging innovation and focusing on client needs, Julie ensures every detail is handled with precision and care.

Julie Krause is a top-performing real estate professional with Coldwell Banker 360 Team, specializing in the Anacortes, WA, region. With years of experience and a focus on personalized, community-driven service, Julie is dedicated to helping clients achieve their real estate goals. Visit her website at juliekrause.cb360team.com to explore her listings and discover why she’s a trusted name in local real estate.

About Julie Krause Real Estate:

As a dedicated real estate professional, Julie Krause combines personalized service with expert insights to help her clients find their perfect home. With a deep understanding of Skagit County’s unique housing market, Julie has established herself as a leading agent in the region, offering unmatched expertise and unwavering dedication to her clients.

Media Contact
Company Name: Coldwell Banker 360 Team
Contact Person: Julie Krause
Email: Send Email
Country: United States
Website: https://juliekrause.cb360team.com

Glaucoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Glaucoma Pipeline Insight, 2025,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma pipeline landscape. It covers the Glaucoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glaucoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Glaucoma Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Glaucoma Pipeline Outlook Report

Key Takeaways from the Glaucoma Pipeline Report

  • In May 2025, Gainesville Eye Associates announced a study of visual field assessments between the TEMPO, VisuALL, and HFA perimeters. Subjects will be assessed at 1 visit. Clinical evaluations will include MD, PSD, FT, VFI, OCT, and a questionnaire.
  • DelveInsight’s Glaucoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Glaucoma treatment.
  • The leading Glaucoma Companies such as Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
  • Promising Glaucoma Pipeline Therapies such as EYEOP1, Latanoprost 0.005%, POLAT-001, Ranibizumab, Mitomycin (MMC), PRM-151, Triesence, Timolol, latanoprost, Xalatan, Travatan Z and others.

Discover how the Glaucoma treatment paradigm is evolving. Access DelveInsight’s in-depth Glaucoma Pipeline Analysis for a closer look at promising breakthroughs @ Glaucoma Clinical Trials and Studies

Glaucoma Emerging Drugs Profile

  • GmbH NCX 470: Nicox Ophthalmics

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog that is currently being developed by Nicox Ophthalmics. NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470’s dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

  • DE-126: Santen Pharmaceuticals

DE-126 (ONO-9054) is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, ONO-9054 is expected to give a new therapeutic options for the treatment of glaucoma. It is likely to show a superior IOP lowering effect compared to FP receptor agonists. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

  • POLAT 001: Peregrine Ophthalmic

POLAT-001 is a sustained released product of latanoprost for the medical treatment of glaucoma. The drug is a 100 nm-long nanoliposome containing latanoprost. Lipolat is an extended release drug delivery solution that is a ground breaking development in nanomedicine for ophthalmology. Liposomal latanoprost has completed a pilot Phase IIa trial in the US for glaucoma indication.

  • BTQ-1902: Betaliq, Inc.

BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta blocker. Beta blockers are one of the most commonly prescribed classes of medicines to treat glaucoma. Beta blockers reduce Intraocular Pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Beta blockers are often prescribed in combination with other glaucoma medications. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Open-Angle Glaucoma.

  • ST266: Noveome Biotherapeutics

ST266 is a non-cellular biologic drug candidate, currently considered “investigational,” since it is not yet approved by the U.S. Food and Drug Administration (FDA). The clinical trials are designed to examine and confirm that ST266 is safe and effective in humans with the goal of bringing this unique product to potentially millions of patients who suffer from complex diseases and conditions in ophthalmology, neurology, dermatology—and beyond. ST266 is made by the proprietary method of culturing amnion epithelial cells that are harvested from donated full-term placentas normally discarded after birth. It contains hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. These various proteins and factors are delivered in physiologic concentrations that have been shown, in preclinical and clinical studies to date, to be well-tolerated with demonstrated biologic activity. In preclinical studies, ST266 has been shown to be neuroprotective and to resuscitate damaged and diseased retinal ganglion cells, offering the possibility of a novel treatment for glaucoma. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Glaucoma.

The Gastroparesis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Gastroparesis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroparesis Treatment.
  • Gastroparesis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroparesis market

Explore groundbreaking therapies and clinical trials in the Gastroparesis Pipeline. Access DelveInsight’s detailed report now! @ New Gastroparesis Drugs

Glaucoma Companies

Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.

Glaucoma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Glaucoma Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Glaucoma Market Drivers and Barriers, and Future Perspectives

Scope of the Glaucoma Pipeline Report

  • Coverage- Global
  • Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
  • Glaucoma Pipeline Therapies- EYEOP1, Latanoprost 0.005%, POLAT-001, Ranibizumab, Mitomycin (MMC), PRM-151, Triesence, Timolol, latanoprost, Xalatan, Travatan Z and others.
  • Glaucoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Glaucoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Glaucoma drug development? Find out in DelveInsight’s exclusive Glaucoma Pipeline Report—access it now! @ Glaucoma Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Glaucoma Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Glaucoma Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NCX 470: Nicox Ophthalmics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. POLAT 001: Peregrine Ophthalmic
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ST266: Noveome Biotherapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. RTC-1119: Ripple Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Glaucoma Disease Key Companies
  21. Glaucoma Disease Key Products
  22. Glaucoma Disease- Unmet Needs
  23. Glaucoma Disease- Market Drivers and Barriers
  24. Glaucoma Disease- Future Perspectives and Conclusion
  25. Glaucoma Disease Analyst Views
  26. Glaucoma Disease Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glaucoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glaucoma Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Hidradenitis Suppurativa Pipeline Appears Robust With 24+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Hidradenitis Suppurativa Pipeline Insight 2025” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the Hidradenitis Suppurativa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hidradenitis Suppurativa Treatment Landscape. Click here to read more @ Hidradenitis Suppurativa Pipeline Outlook

Key Takeaways from the Hidradenitis Suppurativa Pipeline Report

  • In June 2025, Merck Sharp & Dohme LLC announced a study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
  • In June 2025, ACELYRIN Inc. conducted a study will evaluate the efficacy, safety, and immunogenicity of izokibep administered subcutaneously (SC) in adult subjects with moderate to severe HS.
  • In June 2025, Incyte Corporation organized a study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
  • In June 2025, Avalo Therapeutics Inc. announced a Phase 2 study. Patients will be randomized to one of two AVTX-009 dose regimens or matching placebo in a 1:1:1 ratio.
  • In June 2025, Novartis Pharmaceuticals conducted a study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
  • DelveInsight’s Hidradenitis Suppurativa pipeline report depicts a robust space with 24+ active players working to develop 24+ pipeline therapies for Hidradenitis Suppurativa treatment.
  • The leading Hidradenitis Suppurativa Companies such as InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.
  • Promising Hidradenitis Suppurativa Pipeline Therapies such as Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.

Discover groundbreaking developments in Hidradenitis Suppurativa therapies! Gain in-depth knowledge of key Hidradenitis Suppurativa Clinical trials, emerging drugs, and market opportunities @ Hidradenitis Suppurativa Clinical Trials Assessment

Hidradenitis Suppurativa Emerging Drugs Profile

  • Vilobelimab: InflaRx

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. Vilobelimab has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. Vilobelimab is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with vilobelimab in clinical trials, and the antibody has been shown to be well tolerated. Vilobelimab is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum, cancer and severe COVID‑19. 

  • Secukinumab: Novartis

Secukinumab is the first and only fully human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)12,13. Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis, PsA and AS14-20. These data strengthen the position of Cosentyx as a treatment across AS, nr-axSpA, PsA and moderate to severe plaque psoriasis, supported by more than 500,000 patients treated worldwide since launch in 2015.

  • Avacopan: ChemoCentryx

Avacopan, approved by the FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in complement-driven autoimmune and inflammatory diseases. While the precise mechanism in ANCA vasculitis has not been definitively established, Avacopan, by blocking the complement 5a receptor (C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, is presumed to arrest the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA vasculitis. Avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing TAVNEOS for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and Lupus Nephritis (LN).

  • Imsidolimab: AnaptysBio

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

  • Spesolimab: Boehringer Ingelheim

Spesolimab is a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogeneses of several autoimmune diseases, including GPP. Spesolimab is also under investigation for the prevention of GPP flares and for the treatment of other neutrophilic skin diseases, such as palmoplantar pustulosis (PPP) and hidradenitis suppurativa (HS).

Hidradenitis Suppurativa Market Drivers

  • Advancements in Research and Development
  • Rise in awareness about the disease

Hidradenitis Suppurativa Market Barriers

  • Stigma and Patient Reluctance
  • Complexity of the disease

The Hidradenitis Suppurativa Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hidradenitis Suppurativa with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa Treatment.
  • Hidradenitis Suppurativa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Hidradenitis Suppurativa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hidradenitis Suppurativa market

Stay informed about the Hidradenitis Suppurativa pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hidradenitis Suppurativa Unmet Needs

Hidradenitis Suppurativa Companies

InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Hidradenitis Suppurativa Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Transform your understanding of the Hidradenitis Suppurativa Pipeline! See the latest progress in drug development and clinical research @ Hidradenitis Suppurativa Market Drivers and Barriers, and Future Perspectives

Scope of the Hidradenitis Suppurativa Pipeline Report

  • Coverage- Global
  • Hidradenitis Suppurativa Companies- InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics and others.
  • Hidradenitis Suppurativa Pipeline Therapies- Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.
  • Hidradenitis Suppurativa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Hidradenitis Suppurativa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Gastroenterology Research–Access the Full Hidradenitis Suppurativa Pipeline Analysis Today! @ Hidradenitis Suppurativa Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hidradenitis Suppurativa: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hidradenitis Suppurativa – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Vilobelimab: InflaRx
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Spesolimab: Boehringer Ingelheim
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. AT193: Azora Therapeutics
  18. Drug profiles in the detailed report…..
  19. Preclinical and Discovery Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Hidradenitis Suppurativa Key Companies
  24. Hidradenitis Suppurativa Key Products
  25. Hidradenitis Suppurativa – Unmet Needs
  26. Hidradenitis Suppurativa – Market Drivers and Barriers
  27. Hidradenitis Suppurativa – Future Perspectives and Conclusion
  28. Hidradenitis Suppurativa Analyst Views
  29. Hidradenitis Suppurativa Key Companies
  30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hidradenitis-suppurativa-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hidradenitis Suppurativa Pipeline Appears Robust With 24+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

AD Ports Group Recognised with Multiple Honours at 2025 Harvard Business Council’s AI & Innovation Awards

Abu Dhabi, UAE – 18 June, 2025 – AD Ports Group (ADX: ADPORTS), a leading facilitator of global trade, logistics, and industry, has won eight prestigious awards at the Harvard Business Council (HBC) 2025 AI & Innovation Convention & International Awards Ceremony. This esteemed event took place at the Royal Society of Arts, Manufactures, and Commerce (RSA) in London, an institution renowned for its dedication to social progress and innovation since 1754.

These accolades are a testament to AD Ports Group’s extraordinary resilience and visionary leadership, solidifying its position at the forefront of the trade and logistics industry.

Eiman Al Khalaqi, Senior Vice President of Innovation, AD Ports Group, said: “We are delighted that the Harvard Business Council has recognised AD Ports Group’s significant achievements throughout 2025. This acknowledgment is a testament to our team’s unwavering commitment to enhancing our services and pushing the boundaries of excellence, driving our Group towards new heights of global leadership and innovation.”

The awards celebrated exceptional achievements in AI integration, sustainability, and innovation across global sectors.

Achievements of AD Ports Group at HBC 2025:

1. Corporate Responsibility Award

Ports Cluster – AD Ports Group, Diamond Winner, has set a gold standard for responsible leadership by aligning their strategy with global sustainability goals and launching impactful initiatives that have touched over one million lives. With strong executive commitment, innovative tools, and a deep focus on people, planet, and prosperity, they have shown how business can be a force for good.

2. Innovation Award

AD Ports Group, Gold Winner, has empowered employees through their IBTIKAR platform to contribute over 18,000 ideas, with more than 50% implemented. This platform has delivered measurable impact in sustainability, digital transformation, and customer value. Their innovation model has been validated by eight consecutive Platinum accreditations, ISO 56002 certification, and a Level 4 Global Innovation Maturity certification from the Global Innovation Management Institute (GIMI).

3. Business Sustainability Award

Noatum Maritime – AD Ports Group, Gold Winner, has set a new global benchmark in green maritime innovation by launching the region’s first all-electric pilot boat and the world’s most powerful electric tug. They are leading the way toward a net-zero future with cutting-edge sustainability practices, circular waste management, and a strong commitment to the UN Sustainable Development Goals (SDG).

4. Business Partnerships Award

Ports Cluster – AD Ports Group, Gold Winner, has redefined global partnership excellence, driving over AED 5 billion into the UAE’s GDP. They have forged alliances across four continents and powered the region’s most advanced, sustainable port network. Their collaborations, including strategic deals in Egypt, Iraq, Jordan, and Pakistan, are shaping the future of trade and connectivity.

5. Innovative Idea Award

SAFEEN Subsea – AD Ports Group, Gold Winner, has developed SAFEEN Green, the region’s first fully autonomous, Unmanned Surface Vessel. This innovation has set a new industry benchmark in efficiency, safety, and sustainability, achieving over 40% cost savings and zero offshore personnel, with a proven track record on high-impact survey projects.

6. Executives Award

Eiman Al Khalaqi, Senior Vice President of Innovation, Gold Winner, has championed a culture of innovation at group scale, leading strategic innovation platforms, achieved global certifications, and fostered enterprise-wide engagement that positioned the Group as a regional benchmark in innovation maturity, sustainability impact, and continuous digital evolution.

7. Professional Award

Ashraf Yaseen, Senior Manager of Business Excellence, Gold Winner, has pioneered excellence frameworks, advanced award innovation, and integrated sustainability into core practices. His initiatives have enabled impactful collaboration and digital transformation, generating strategic value across AD Ports Group and wider maritime sector,while reinforcing its position as a regional leader in business excellence and maritime innovation.

8. Professional Award

Jeffrey Casianan, Executive – HSE, Gold Winner, has significantly enhanced safety performance and operational excellence within the Ports Cluster. Through his active contribution to HSE and CSR initiatives, he helped implement impactful programs that improved outcomes on the ground, driven financial savings, and supported the cluster’s position as a leader in responsible port operations.

This year’s HBC convention and awards ceremony marked a milestone with the global launch of the Intelligent Sustainable Excellence (ISE) Model, alongside the recognition of 63 winners across 30 categories — selected from 4,172 applications and more than 5,500 assessment hours.

The Harvard Business Council International Awards is the global standard for total quality management and continuous improvement. This platform offers organisations from around the world the opportunity to tell their success stories of achieving organisational excellence, adopting best practices, and providing services that meet stakeholders’ expectations.

For media information, please contact:

AD Ports Group Media Office

Email: media@adports.ae

About AD Ports Group:

Established in 2006, AD Ports Group today serves as a globalenabler of trade, logistics, and industry, as well as a bridge linking Abu Dhabi to the world. Listed on the Abu Dhabi Securities Exchange (ADX: ADPORTS), AD Ports Group’s vertically integrated business approach has proven instrumental in driving the Emirate’s economic development over the past decade.

Operating five business clusters covering Ports, Economic Cities & Free Zones, Maritime & Shipping, Logistics, and Digital, AD Ports Group’s portfolio comprises 34 terminals, with a presence in over 50 countries, and more than 550 square kilometres of economic zones within KEZAD Group, the largest integrated trade, logistics, and industrial business grouping in the Middle East.

AD Ports Group is rated “AA-” Outlook stable by Fitch, and “A1” outlook stable by Moody’s.

For more information, please visit: www.adportsgroup.com

Follow AD Ports Group on:

Media Contact
Company Name: Harvard Business Council
Contact Person: HBC International Awards Foundation
Email: Send Email
Country: United States
Website: https://hbcworld.org/cases

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AD Ports Group Recognised with Multiple Honours at 2025 Harvard Business Council’s AI & Innovation Awards